Brief: CSPC Pharmaceutical Says Recombinant Respiratory Syncytial Virus Vaccine Gets Clinical Trial Approval In U.S.
25/08/2026 15:07
BRIEF-CSPC Pharmaceutical Says Recombinant Respiratory Syncytial Virus Vaccine Gets Clinical Trial Approval In U.S. Aug 25 (Reuters) - CSPC PHARMACEUTICAL GROUP LIMITED 1093.HK:
RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (SYS6057) OBTAINS CLINICAL TRIAL APPROVAL IN U.S.
SYS6057 RECEIVES NMPA APPROVAL ON JULY 30, 2026 TO CONDUCT CLINICAL TRIALS IN CHINA
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines